CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

March 17, 2021

Primary Completion Date

July 9, 2025

Study Completion Date

July 9, 2025

Conditions
Non-Small-Cell Lung Cancer
Interventions
BIOLOGICAL

CAB-AXL-ADC

Conditionally active biologic anti-AXL antibody drug conjugate

BIOLOGICAL

PD-1 inhibitor

PD-1 inhibitor

Trial Locations (60)

10016

NYU Langone Health, New York

14263

Roswell Park, Buffalo

15232

UPMC Cancer Center, Pittsburgh

16132

"IRCCS Osp. Policlinico San Martino Pad Ex microbiologia, stanza 9, 1 piano.", Genoa

20141

European Institute of Oncology (IEO), IRCCS, Milan

28041

University Hospital 12 de Octubre, Madrid

28374

FirstHealth Outpatient Cancer Center, Pinehurst

29407

Medical University of South Carolina- Hollings Cancer Center, Charleston

30912

Augusta University - Georgia Cancer Center, Augusta

31008

Clinica Universidad de Navarra, Pamplona

32003

Florida Cancer Specialists & Research Institute, Fleming Island

33401

Florida Cancer Specialists, West Palm Beach

33612

Moffitt Cancer Center, Tampa

33705

Florida Cancer Specialist, St. Petersburg

33916

Florida Cancer Specialists & Research Institute, Fort Myers

37126

Integrated University Hospital of Verona, Verona

37203

Sarah Cannon Research Institute, Nashville

40241

Norton Cancer Institute, Brownsboro Hospital Campus, Louisville

40503

Baptist Health Systems, Lexington

40536

University of Kentucky, Lexington

41014

Hospital Universitario Virgen de Valme, Seville

44718

Gabrail Cancer Research Center, Canton

45219

The Lindner Research Center at the Christ Hospital, Cincinnati

48121

Santa Maria delle Croci Hospital of Ravenna, Ravenna

48202

University of Michigan Comprehensive Cancer Center, Detroit

70809

Hematology/Oncology Clinic, Baton Rouge

75230

Mary Crowley Cancer Research, Dallas

77030

MD Anderson, Houston

80045

University of Colorado Anschutz Medical Campus, Aurora

83100

Hospital San Giuseppe Moscati, Avellino

89014

Comprehensive Cancer Centers of Nevada, Henderson

89169

OptumCare Cancer Care, Las Vegas

90027

California Research Institute, Los Angeles

90033

USC Norris, Los Angeles

90048

Cedars-Sinai, Los Angeles

90603

American Institute of Research, Whittier

91010

City of Hope - Duarte, Duarte

92093

University of California, San Diego (UCSD) - Moores Cancer Center, San Diego

92868

University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center, Irvine

02215

Dana-Farber Cancer Institute, Boston

115 26

Henry Dunant Hospital Center, Athens

185 47

Metropolitan Hospital Perseus Healthcare Group SA, Piraeus

546 22

Bioclinic Thessaloniki, Thessaloniki

570 01

European Interbalkan Medical Center, Thessaloniki

Unknown

ICON Cancer Centre, Hong Kong

Queen Mary Hospital, Hong Kong

Hong Kong United Oncology Centre, Kowloon

Kaoshiung Chang Gung Memorial Hospital, Kaohsiung City

Taichung Veterans General Hospital, Taichung

National Cheng Kung University Hospital, Tainan City

National Taiwan University Hospital, Taipei

Taipei Veterans General Hospital, Taipei

60-693

MED-Polonia, Sp. z o.o. (LLC), Poznan

20-609

Institute of Genetics and Immunology GENIM, Lublin

02-781

Maria Sklodowska-Curie - National Research Institute of Oncology, Warsaw

93-338

Polish Mother's Memorial Hospital-Research Institute, Lodz

97-200

Specialistic Oncologic Hospital NU-MED, Tomaszów Mazowiecki

08003

Hospital del Mar, Barcelona

08041

Hospital de la Santa Creu i Sant Pau, Barcelona

08908

Catalan Institute of Oncology, Hospital Duran i Reynals, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BioAtla, Inc.

INDUSTRY

NCT04681131 - CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC | Biotech Hunter | Biotech Hunter